DNT and EMD Biosciences sign siRNA and DNA reagent license and supply agreement

21-Feb-2007

Dendritic Nanotechnologies Inc (DNT), a Starpharma Holdings Company, has entered into a worldwide exclusive license and supply agreement with EMD Biosciences, part of Merck KGaA's Performance and Life Science Chemicals division.

Under the terms of this agreement, DNT will supply EMD Biosciences with PrioFect(TM) transfection reagents based on Priostar(TM) proprietary dendrimers for the DNA and siRNA transfection research markets. Terms of the agreement which includes royalties and milestone payments were not disclosed.

DNT's PrioFect transfection reagents are part of the market for nucleic acid, DNA and small interfering RNA (siRNA) research. According to the company, PrioFect transfection reagents are the only transfection reagents with nanometer-size control.

Under this commercial arrangement DNT retains full rights to all in vivo aspects of transfecting nucleic acids with Priostar technology.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances